ArticleInternational journal of clinical and experimental pathology2017
MicroRNA-181a knockdown protects HepaRG cells from Dichlorvos-induced oxidative stress and apoptosis.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 6 citations in OpenAlex.
- Modulation of miR-181 influences dopaminergic neuronal degeneration in a mouse model of Parkinson's disease.Molecular therapy. Nucleic acids · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study was designed to assess the molecular mechanism of Dichlorvos (DDVP)-induced hepatic cell toxicity in vitro using HepaRG cells. The cytotoxicity was determined by cell viability, apoptosis portion, and reactive oxygenspecies (ROS) generation. The results indicated that DDVP treatment significantly inhibited cell growth, induced cell apoptosis and promoted the production of ROS on HepaRG cells. Microarray analysis showed that miR-181a was significantly upregulated in HepaRG cells treated with DDVP. Furthermore, we found that miR-181a downregulation has a remedy effect on DDVP-induced cell toxicity, while miR-181a overexpression augments the DDVP-induced hepatic cell apoptosis and ROS production. Furthermore studies showed that miR-181a directly targeted Bcl-2, and Bcl-2 downregulation inhibited the remedy effect of miR-181a inhibitor on DDVP induced cell toxicity. It is, therefore, concluded that miR-181a knockdown could protect hepatic cells from DDVP induced oxidative stress and apoptosis by targeting bcl-2.
Indexed as
Identifiers
31966431PMC6965843W3026089394What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.